Information
Cyclophosphamide + Methotrexate + 5-Flourouracil (CMF-IV Regimen)1,46- Prechemo: CBC, Chem, LFTs, and CA 27–29. 5-HT3 and dexamethasone 20 mg. Moderately to highly emetogenic.
- Cyclophosphamide 600 mg/m2: IV in 500–1000 cc NS IV on day 1.
- Methotrexate 40 mg/m2: IV on day 1.
- 5-Flourouracil 600 mg/m2: IV on day 1.
- Side effects: Cyclophosphamide can cause rhinitis and irritation of nose and throat. Myelosuppression can be severe. Thrombocytopenia and anemia mild. Nausea and vomiting. Mucositis and diarrhea can be severe, dose dependent. Acute renal failure, azotemia, urinary retention, and uric acid nephropathy have been observed with methotrexate. Hemorrhagic cystitis, dysuria, and urinary frequency with cyclophosphamide. SIADH. Photophobia, increased lacrimation, acute and chronic conjunctivitis, blepharitis, and blurred vision. Alopecia. Hyperpigmentation of nails and skin, banding of nails, and radiation recall may occur. Photosensitivity, sunburn-like rash. Hand-foot syndrome can be dose-limiting.
- Chair time: 2 hours on day 1. Repeat cycle every 21 days for six cycles.